A study for patients with newly diagnosed Chronic Phase Myeloid Leukaemia evaluating the drug Asciminib.

Abstract

This purpose of this study is to evaluate the efficacy of asciminib in newly diagnosed patients with chronic phase chronic myeloid leukaemia.

Who is it for?

You may be eligible for this study if you are an adult who has been newly diagnosed with chronic phase chronic myeloid leukaemia.

Study details

Eligible participants in this study will receive asciminb 40mg (oral) twice a day for up to five years.

Dose reduction or increase may occur depending on the patients tolerability and blood results. The investigator will review every 3 months.

During the trial patients will have blood tests performed and bone marrow samples taken to help determined the progress of the treatment.

It is hoped that this research will help determine the efficacy of this treatment, and what kinds of side effects/complications may occur with this treatment.